Ace Therapeutics provides our customers worldwide who develop diagnostic technology for non-alcoholic fatty liver disease (NAFLD) diagnostics with the innovative solutions they need to succeed. Our technical expertise and innovative services support the development of NAFLD diagnostics in all aspects.
There are two main subtypes of NAFLD, including non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). With the global epidemic of obesity-related metabolic syndrome, the prevalence of NAFLD is increasing and effective diagnostic techniques for NAFLD are becoming increasingly important.
What Can We Do?
Diagnosis of NAFLD requires the identification of pathologic liver fat. There is no convenient method to diagnose fatty liver. Based on years of practical experience and the improvement of theoretical systems, we have established a series of service systems for the development of diagnostic technologies for NAFLD. We will start with screening and optimizing biomarkers and imaging markers for NAFLD, with the aim of improving the diagnosis of NAFLD from various perspectives.
The high stability and sensitivity of ncRNA make it an ideal biomarker for diagnostic use. We offer comprehensive services to screen and identify ncRNAs that are specific to NAFLD.
NAFL miR-122, miR-192, miR-16, miR-21, miR-27b
NASH miR-122, miR-192, miR-16, miR-21
FIBROSIS miR-122, miR-192, miR-16, miR-27b
- Omics-Based Biomarkers for NAFLD
Based on technologies such as genomics, proteomics, and metabolomics, we can provide you with the rapid screening of a large number of biomarkers against different pathways of action of the NAFLD process to accelerate biomarker discovery.
Based on clinical studies, basal hemoglobin, bile acids, glutathione, short fatty acids, arachidonic acid, and lipid oxidation products, have significant changes in NAFLD patients. We will develop the most appropriate service plan for you based on your research project.
- Imaging Biomarkers for NAFLD
Based on our full range of equipment and advanced technology, we will identify more accurate and comprehensive NAFLD imaging biomarkers and optimize the process and results for NAFLD imaging.
Ultrasound-based biomarkers Attenuation parameter, backscatter coefficient, speed/wavelength, acoustic resonance-forced impulse imaging, shear wave elastography
Magnetic resonance-based biomarkers Magnetic resonance imaging proton density fat fraction
MRI-based biomarkers Magnetic resonance elastography
Excellent experts in different fields and rich practical experience make Ace Therapeutics an important partner in the development of diagnostic technologies for NAFLD. We save researchers precious time in their discovery cycle. If you would like to learn more about our services, please feel free to contact us.
Reference
- Han, S., et al., Long non-coding rnas in liver diseases: Focusing on nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease. Clin Mol Hepatol, 2020. 26(4): p. 705-714.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
